Page 2 of 6 – SEC Filing CUSIP No. 897238309 Page 2
1 NAME OF REPORTING PERSON Bridger Management, LLC 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☒ 3 SEC USE ONLY 4 SOURCE OF FUNDS OO (See Item 3) 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ☐ 6 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE VOTING POWER 0 8 SHARED VOTING POWER 3,290,587 9 SOLE DISPOSITIVE POWER 0 10 SHARED DISPOSITIVE POWER 3,290,587 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,290,587 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ☐ 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 11.0% (1) 14 TYPE OF REPORTING PERSON IA
(1) Based on the 29,782,810 shares of common stock disclosed by the Issuer as outstanding as of March 21, 2016, as reported by the Issuer in its Form DEF 14A filed with the Securities and Exchange Commission on March 31, 2016.
Follow Cardiff Oncology Inc. (NASDAQ:CRDF)
Follow Cardiff Oncology Inc. (NASDAQ:CRDF)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
| CUSIP No. 897238309 | Page 2 |
| 1 | NAME OF REPORTING PERSON | ||||
| Bridger Management, LLC | |||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | ||||
| (a) ☐ (b) ☒ | |||||
| 3 | SEC USE ONLY | ||||
| 4 | SOURCE OF FUNDS | ||||
| OO (See Item 3) | |||||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) | ||||
| ☐ | |||||
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION | ||||
| Delaware | |||||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER | |||
| 0 | |||||
| 8 | SHARED VOTING POWER | ||||
| 3,290,587 | |||||
| 9 | SOLE DISPOSITIVE POWER | ||||
| 0 | |||||
| 10 | SHARED DISPOSITIVE POWER | ||||
| 3,290,587 | |||||
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | ||||
| 3,290,587 | |||||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | ||||
| ☐ | |||||
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) | ||||
| 11.0% (1) | |||||
| 14 | TYPE OF REPORTING PERSON | ||||
| IA | |||||
| (1) | Based on the 29,782,810 shares of common stock disclosed by the Issuer as outstanding as of March 21, 2016, as reported by the Issuer in its Form DEF 14A filed with the Securities and Exchange Commission on March 31, 2016. |
Follow Cardiff Oncology Inc. (NASDAQ:CRDF)
Follow Cardiff Oncology Inc. (NASDAQ:CRDF)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
